Tag
This study identifies key prognostic factors and proposes a graded prognostic assessment to stratify survival in patients with brain metastases from nonanaplastic follicular cell-derived thyroid carcinoma.
A Phase 3 randomized trial reveals that stereotactic radiation significantly outperforms hippocampal-avoidance whole brain radiation in reducing symptom severity and interference with daily living for patients with 5 to 20 brain metastases,
The PHENOMENAL phase 2 study reveals that liposomal irinotecan (nal-IRI) achieves a 22% intracranial objective response rate in patients with HER2-negative breast cancer and brain metastases, addressing a critical unmet need in neuro-oncolo
The Phase 3 METIS trial demonstrates that Tumor Treating Fields (TTFields) following stereotactic radiosurgery significantly prolongs time to intracranial progression in NSCLC patients with brain metastases, without compromising neurocognit
The GASTO-1053 phase II study demonstrates that combining bevacizumab with fractionated stereotactic radiotherapy significantly improves intracranial progression-free survival (18.3 months) and quality of life for NSCLC patients with extens
The TUXEDO-3 trial demonstrates that patritumab deruxtecan, a HER3-targeted antibody-drug conjugate, offers clinical benefit and a manageable safety profile in metastatic breast cancer patients with active brain metastases.
A prospective phase II trial shows stereotactic radiosurgery offers a low neurologic death rate in SCLC patients with 1-10 brain metastases, challenging the traditional favoring of whole-brain radiation therapy.
A phase 3 randomized trial demonstrates that preoperative stereotactic radiation therapy (SRT) for brain metastases offers comparable safety and reduced treatment duration compared to postoperative SRT, potentially improving patient care lo
The ACHIEVE Phase 2 trial reveals that high-dose aumolertinib offers significant intracranial and systemic control with a manageable safety profile in patients with untreated EGFR-mutant NSCLC and brain metastases, highlighting its therapeu
